As perinatally human immunodeficiency virus-infected youth (PHIVY) in the United States grow older and more treatment experienced, clinicians need updated information about the association of age, CD4 cell count, viral load (VL), and antiretroviral (ARV) drug use with risk of opportunistic infections, key clinical events, and mortality to understand patient risks and improve care. , we estimated event rates during person-time spent in key strata of age (7-12, 13-17, and 18-30 years), CD4 cell count (<200, 200-499, and Ն500/μL), and a combined measure of VL and ARV status (VL <400 or Ն400 copies/mL; ARV therapy or no ARV therapy). A total of 1562 participants in the PHACS Adolescent Master Protocol and IMPAACT P1074 were eligible, and 1446 PHIVY from 41 ambulatory sites in the 12 US states, including Puerto Rico were enrolled. The dates of analysis were March 2015 through January 2017. . During a mean (SD) follow-up of 4.9 (1.3) years, higher incidences of CDC-B events, CDC-C events, and mortality were observed as participants aged. Older PHIVY (aged 13-17 and 18-30 years) spent more time with a VL of 400 copies/mL or more and with a CD4 cell count of less than 200/μL compared with 7-to 12-year-old participants (30% and 44% vs 22% of person-time with a VLՆ400 copies/mL; 5% and 18% vs 2% of person-time with CD4 cell count <200/μL; P < .001 for each comparison). We observed higher rates of CDC-B events, CDC-C events, bacterial infections, and mortality at lower CD4 cell counts, as expected. The mortality rate among older PHIVY was 6 to 12 times that among the general US population. Higher rates of sexually transmitted infections were also observed at lower CD4 cell counts after adjusting for age.
sion have decreased among PHIVY in the United States since the implementation of effective combination antiretroviral therapy (cART) but may remain higher for older PHIVY. 4, 5 Compared with adults, PHIVY experience lower rates of HIV RNA viral load (VL) suppression and higher rates of loss to follow-up. [6] [7] [8] As youth age and transition to adult care, their risks of opportunistic infections (OIs), other serious clinical events, and mortality are not well described. [9] [10] [11] [12] [13] [14] Understanding the frequency of important clinical events for PHIVY, as well as the consequences of being prescribed cART without a suppressed VL, will provide critical information to design interventions for this group, who are at risk for severe illness, accumulation of drug-resistance mutations, and secondary transmission. 15, 16 Our objectives were to determine the frequency of viremia and immunosuppression among PHIVY and young adults aged 7 to 30 years engaged in care in 2 large national cohort studies and to analyze associations among age, CD4 cell count, viremia, antiretroviral (ARV) drug use, and risks of significant clinical events and mortality.
Methods

Study Population
We . 17 For this analysis, PHACS AMP participants were eligible if they had 1 or more visits from March 2007, through April 2015, and 1 or more CD4 cell count and VL measurements recorded after baseline. IMPAACT P1074 participants were eligible if they were PHIVY and had 1 or more medical record abstractions with CD4 cell count and VL data recorded after baseline. The PHACS AMP baseline was defined as date of study entry; the IMPAACT P1074 baseline was defined as 1 year before study entry. Simultaneous coenrollment in PHACS AMP and IM-PAACT P1074 was not permitted. On the basis of guidelines, practice patterns, and trial data, we defined cART regimens as 1 of 3 mutually exclusive types expected to be suppressive: (1) 3 or more drugs from 2 or more classes, (2) a protease inhibitor (excluding ritonavir alone) plus 1 drug from another class, or (3) 3 or more nucleos(t)ide reverse transcriptase inhibitors. 2, [18] [19] [20] [21] [22] We excluded person-time when patients had VLs of less than 400 copies/mL and were not prescribed ARV drugs and when patients had VLs of 400 copies/mL or higher while being prescribed an ARV regimen other than cART. Although individual patient circumstances may have warranted these approaches, they are not expected to suppress VL and were not standard of care during the study period. 2, [18] [19] [20] [21] [22] Loss to follow-up was defined as stopping data collection for any reason other than death, study completion, or site closure. The study protocols for PHACS AMP and IMPAACT P1074 were approved by the institutional review board of each participating site. The Harvard T.H. Chan School of Public Health (Boston, Massachusetts) Institutional Review Board also approved the PHACS AMP study protocol and all work undertaken by the IMPAACT Network. For both studies, written informed consent was obtained from all participants and/or families, with written assent obtained for minors according to local institutional review board guidelines. For analysis, data were deidentified. cell count, and VL data at any point during follow-up; 1 who spent his or her entire person-time in the study with a VL of 400 copies/mL or higher while prescribed a regimen other than cART; and 2 who spent their entire person-time with a VL less than 400 copies/mL while not prescribed ARV drugs. We excluded 92.3 person-years (1.4% of overall person-time) while participants were viremic and prescribed a regimen other than cART and 59.4 person-years (0.9% of overall person-time) while participants had a VL less than 400 copies/mL while not prescribed ARV drugs, from a total of 247 participants. Table 1 reports additional baseline and follow-up characteristics. Of note, patients who were lost to follow-up differed significantly from retained patients only in baseline age (15.8 vs 14.4 years).
Results
Characteristics of the Study Population
Distribution of Person-time
Participants contributed 19% of person-time between the ages of 7 and 12 years, 38% between the age of 13 and 17 years, and 43% between the ages of 18 and 30 years; only 2% of total person-time was between the ages of 26 and 30 years ( Table 2) . Most persontime was spent with CD4 cell counts of 500/μL or more (65% of person-time compared with 24% at CD4 cell counts of 200-499/ μL and 10% at CD4 cells counts <200/μL) and prescribed suppressive ARV therapy (66% of person-time compared with 28% in those prescribed nonsuppressive cART and 7% in those taking no ARV drugs). Person-years spent in older age strata (13-17 and 18-30 years) compared with ages 7 to 12 years were more likely to be spent with CD4 cell counts of less than 200/μL (5% and 18% vs 2%; P < .001 for each pairwise comparison). For older PHIVY (aged 13-17 and 18-30 years), more person-time was also spent with a VL of 400 copies/mL or more (nonsuppressive cART or no ARVs drug use, 30% for those 13-17 years old and 44% for those 18-30 years old vs 22% for PHIVY 7-12 years old; P < .001 for both). When the older age stratum was further divided into 18 to 21, 22 to 25, and 26 to 30 years, the proportions of time spent being viremic and with low CD4 cell counts remained substantially higher for each substratum compared with younger ages (Table 3) . Prescription of nonsuppressive cART was not associated with having a CD4 cell count of less than 200/μL compared with use of no ARV drugs (25% vs 24% of person-time; P = .72).
Mortality
Overall, there were 29 deaths (0.4 per 100 person-years) (eTables 1-4 in the Supplement). A total of 23 deaths (79.3%) occurred at CD4 cell counts of less than 200/μL (3.5 per 100 person-years). A total of 24 deaths (82.3%) occurred while VL was 400 copies/mL or higher, with mortality rates of 0.9 per 100 person-years for nonsuppressive cART and 1.6 per 100 person-years for no ARV drug use (P < .001 for trend). All but 1 death (96.6%) occurred in 18-to 30-year-old participants (1.0 per 100 person-years; P < .001 for trend). Mortality rates were 5.6-fold (95% CI, 2.8-11.1) higher among those aged 15 through 19 years and 12.3-fold (95% CI, 8.0-18.9) higher among those aged 20 through 29 years than youth of the same age in the US general population.
34
First Events During Follow-up
CDC-C and WHO-4 Events
There were 86 CDC-C and WHO-4 events (1.4 per 100 personyears) (eTable 5 in the Supplement). Higher rates of CDC-C and WHO-4 events were observed at lower CD4 cell counts (<200/ μL: 9.6 per 100 person-years; 200-499/μL: 1.0 per 100 personyears; ≥500/μL: 0.4 per 100 person-years; P < .001 for trend).
Of 17 events that occurred at CD4 cell counts of 500/μL or less (20% of total), only 2 were OIs (pulmonary tuberculosis and ocular toxoplasmosis); others were HIV-related kidney and cardiac diseases. Higher rates of CDC-C and WHO-4 events occurred with higher VL (suppressive ARV therapy: 0.6 per 100 person-years; nonsuppressive cART: 3.0 per 100 personyears; no ARV therapy: 2.4 per 100 person-years; P < .001 for trend). Higher rates of CDC-C and WHO-4 events were also observed with older age (7-12 years of age: 0.7 per 100 personyears; 13-17 years of age: 0.9 per 100 person-years; 18-30 years of age: 2.1 per 100 person-years; P < .001 for trend).
CDC-B and WHO-3 Events
There were 193 CDC-B and WHO-3 events (3.2 per 100 personyears) ( Figure 1, Figure 2 , and eTable 6 in the Supplement).
Higher rates of CDC-B and WHO-3 events were observed at lower CD4 cell counts (<200/μL: 12.5 per 100 person-years; 200-499/μL: 3.8 per 100 person-years; ≥500/μL: 1.8 per 100
person-years; P < .001 for trend). The CDC-B and WHO-3 events were also more common at higher VL (suppressive ARV therapy: 2.0 per 100 person-years; nonsuppressive cART: 5.5 per 100 person-years; no ARV therapy: 7.1 per 100 personyears; P < .001 for trend). These event rates also increased as participants aged (7-12 years old: 2.4 per 100 person-years; 13-17 years old: 2.9 per 100 person-years; 18-30 years old: 3.9 per 100 person-years; P = .01 for trend). For bacterial pneumonia (CDC-B and WHO-3 event) and serious bacterial infections, higher event rates were also observed at lower CD4 cell counts and higher VLs, but no trends were observed by age (eTable 7 and eTable 8 in the Supplement).
Reproductive System Events
In female participants, higher rates of presumptive PID, other STIs, and pregnancies were observed with older age and with VLs higher than 400 copies/mL (eTables 9-11 in the Supplement); higher rates of STIs (not including PID) and pregnancy were observed with lower CD4 cell counts. After adjusting for age, the association between increasing rates of pregnancies and lower CD4 cell counts was not statistically significant (<200/μL: 4.5 per 100 person-years; 200-499/μL: 4.8 per 100 person-years; ≥500/μL: 2.8 per 100 person-years; P = .18); however, the trend of increased rates of first female STI at lower CD4 cell counts remained significant (<200/μL: 8.1 per 100 person-years; 200-499/μL: 5.9 per 100 person-years; ≥500/μL: 3.1 per 100 person-years; P < .001). First STIs were infrequently reported in males (eTable 12 in the Supplement).
Other Clinical Events
Mental health and neurodevelopmental conditions were among the most frequent conditions (4.0 per 100 personyears); no trends were observed by age, CD4 cell count, or VL and ARV status (eTable 13 in the Supplement). For asthma, 
Discussion
We analyzed rates of clinical events and mortality during 6548 person-years of follow-up from 1446 PHIVY aged 7 to 30 years in PHACS AMP and IMPAACT P1074 cohort studies, stratified by time-updated age, CD4 cell count, and VL and ARV status. There were 3 key findings from this work. First, older youth were at highest risk for viremia, low CD4 cell counts, and serious clinical events, including mortality, CDC-C and WHO-4 events, and CDC-B and WHO-3 events. Monitoring of VL remained consistent across age ranges, suggesting ongoing engagement in care; thus, high overall rates of viremia among participants aged 18 to 30 years are likely attributable to suboptimal medication adherence or acceptance or accumulated viral resistance. Older PHIVY had greater early exposure to monoregimens or dual regimens compared with younger PHIVY; the lack of viral suppression among those PHIVY prescribed cART is more likely related to poor medication adherence or acceptance because resistance to newer ARV drugs, such as integrase inhibitors, is uncommon. 35 Older youth also spent more time with CD4 cell counts less than 200/μL. Data from PHIVY aged 6 to 17 years suggest that having a CD4 cell count less than 200/μL is associated with lower quality of life, psychiatric symptoms, and poor cognitive, academic, and social functioning, and data from adults suggest high risks of OIs and death. 36, 37 Our findings are consistent with increasing literature that outlines the challenges to adhering to medications for PHIVY in adolescence, which intensify as PHIVY reach early adulthood.
38-43
Second, we observed relatively few clinical events and deaths during the follow-up period, during which cART was standard of care. These results add to prior reports However, the mortality rate in older adolescent PHIVY (aged 15-19 years) remained 6 times and in young adult PHIVY (aged 20-29 years) remained 12 times that of the US general population, after accounting for age, sex, and race. The STIs among female participants and mental health and neurodevelopmental diagnoses were among the most commonly documented conditions. Higher STI rates (excluding PID) among female participants were associated with lower CD4 cell counts after adjusting for age. This finding and the association of lower CD4 cell count with herpes simplex virus reactivation and lack of human papillomavirus clearance have been previously reported. [28] [29] [30] [45] [46] [47] [48] [49] These data suggest a potential biological effect of immunosuppression; in addition, more frequent risk behavior among patients incompletely adherent to cART may higher among those with lower CD4 cell counts, although the strength of this association decreased after age adjustment. Complications potentially related to long-term ARV therapy, including anemia, pancreatitis, hepatitis, peripheral neuropathy, and metabolic and bone abnormalities, were documented infrequently, likely reflecting use of less toxic ARV drugs over time. 35, 51 Third, our person-time results add a valuable dimension to the literature base of cross-sectional and longitudinal studies on viremia in PHIVY. In PHACS AMP and IMPAACT P1074 cohorts described here, 66% of person-time was spent with VLs less than 400 copies/mL, similar to that observed in the HIV Research Network (63% of PHIVY aged 12-21 years with VLs less than 400 copies/mL during 2009-2012). However, viral suppression is higher than that reported in the Adolescent Trials Network (37% of PHIVY with VLs below the lower level of detection) and in a recent meta-analysis (pooled North America estimate of youth with suppressed VLs: 53% [range, 28%-75%] of youth aged 12-24 years during 1990-2013). 4, 8, 52 Although lower suppression rates in the meta-analysis cohorts may reflect the inclusion of non-PHIVY, lower suppression rates for PHIVY in the Adolescent Trials Network cohort may reflect older age in that cohort (mean age, 17.9 vs 14.6 years for the Adolescent Trials Network cohort vs our combined cohorts). In contrast to data from adults, we found that having VLs of 400 copies/mL or higher while being prescribed cART did not improve immunosuppression compared with having VLs of 400 copies/mL or higher while taking no ARVs at all.
53-61
The 35% of person-time spent with VLs of 400 copies/mL or higher in our study raises critical concerns not only for individual patient outcomes but also for the HIV epidemic among US youth. 30, 35, 62 Youth who are viremic despite being engaged in care are more likely to have drug-resistant virus and to report lower condom use than nonviremic youth and thus are at risk of secondary horizontal or vertical transmission.
63-65
Limitations This analysis of PHIVY in 2 large cohort studies had several limitations. First, the smallest proportion of person-time (19%) was spent at ages 7 to 12 years of age; nevertheless, we had adequate power for all statistical comparisons. Second, data collection protocols in the 2 cohorts may have affected incidence rate estimates for specific events because: (1) we analyzed first events, we could not identify recurrent bacterial pneumonia, potentially underestimating CDC-C events; (2) STI screening was not performed at study-specific intervals but per local care practice; and (3) care sought by participants at nonstudy health care facilities was recorded only if reported to study staff. In addition, IMPAACT P1074 recorded only events deemed to be clinically significant by health care professionals, whereas PHACS AMP recorded all events; we addressed this limitation by including only events that met the reporting threshold for both studies (eg, laboratory-value diagnoses were excluded). Furthermore, PHIVY least engaged in care and at highest risk for adverse outcomes may not have been included. Conversely, to permit consistent coding of events between PHACS AMP and IMPAACT P1074 studies, we excluded events before baseline, which may have led to overestimation of some first event rates. Finally, adherence data were not included in the analysis because adherence measures were collected only in 1 study (PHACS AMP). Despite these counterbalancing possibilities, to our knowledge, this analysis provides the most recent, detailed data available about clinical risks in US PHIVY over time. This information will be critical information for US policy makers as research and programmatic funding shifts for pediatric HIV infection in the United States.
66
Conclusions
We found that serious clinical events, including OIs and death, are rare in PHIVY receiving suppressive ART, but viremia, lower CD4 cell counts, and rates of serious clinical events and mortality increase throughout adolescence and young adulthood. Interventions to improve ART adherence and optimize models of care as PHIVY age are urgently needed to improve long-term outcomes among this increasing and vulnerable population. 
